Loading patent…
AssigneePolynum Scientific Immunbiologische Forschung GmbH
InventorsHermann Katinger, Andrea Buchacher, Wolfgang Ernst, Claudia Ballaun, Martin Purtscher, Alexandra Trkola, Renate Predl, Christine Schmatz, Annelies Klima, Franz Steindl, Thomas Muster
Estimating the term…
Disclosed are antibodies which can be used for the manufacture of vaccines for active and/or passive immunization of persons in need of such treatment. The invention also provides for human monoclonal antibodies that are functionally equivalent to the above-mentioned antibodies produced by any one of the cell lines CL1 through CL6 (deposited at the European Collection of Animal Cell Cultures (ECACC) at the PHLS in Porton Down, Salisbury, UK). Also provided are hybridoma and/or CHO cell lines producing any one of the antibodies disclosed and claimed herein. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention and/or therapeutical treatment of HIV-1 infections in vitro and in vivo.
An HIV-1 neutralizing human monoclonal antibody that binds to two different antigenic determinants of gp120 HIV-1 in vitro.
An HIV-1 neutralizing antibody which binds to two different antigenic determinants of HIV-1 and which is induced upon immunization of an animal or human individual with an antibody obtained from cell line CL5 (ECACC Accession No. 95032240) or CL6 (ECACC Accession No. 95032241).
Dependencies are inferred from the claim text.